HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Democratic Senators ask FDA to set maximum lead limits for lipstick. More news in brief.

You may also be interested in...



Campaign for Safe Cosmetics Wants Cap On Lipstick Lead, Proposes 0.026 PPM

The Campaign for Safe Cosmetics is not satisfied with FDA’s safety conclusions regarding lead in lipstick, asking for more data and pointing to a new CDC report suggesting there is no safe level of lead for children. The activist group has launched a new campaign singling out L’Oreal as the “worst offender” in selling “lead-laden” lipsticks, based on FDA test results posted in December.

FDA's Dickinson Named Acting Chief Counsel Following Tyler’s Departure

FDA has tapped Elizabeth Dickinson for acting chief counsel, effective Aug. 7. Dickinson is taking the post on an interim basis while the agency seeks a permanent successor to Ralph Tyler.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel